



Diphtheria and Tetanus Toxoids
and Acellular Pertussis, Inactivated
Poliovirus, Haemophilus b Conjugate
and Hepatitis B Vaccine

CAN 2-3 FEWER SHOTS WITH VAXELIS

LEAD TO IMPROVED EFFICIENCIES IN YOUR PRACTICE?

With 2-3 fewer shots in the infant vaccination series compared to pentavalents (+ hepatitis B or Hib vaccine), VAXELIS may help simplify some aspects of vaccine-related tasks¹⁻⁶

**Learn More About How VAXELIS
May Impact Your Practice**



Office



Staff



Patients

Indication

VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to *Haemophilus influenzae* type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information

- Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
- Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.

Important Safety Information continues on next page



Transitioning your practice to VAXELIS now may lead to improved efficiencies that may impact your practice, staff, and patients¹⁻⁹

VAXELIS requires 2 to 3 fewer shots than with pentavalent vaccines (+ hepatitis B or Hib vaccine) over the infant series¹⁻⁴



Office

No reconstitution and fewer shots results in fewer needles needed across the infant vaccine series, and less needles to dispose of.¹⁻⁴



Staff

Reduction in tasks associated with billing, ordering, and vaccine preparation - which may help save time and improve efficiencies with administrative responsibilities.¹⁻⁸



Patients

Less of a shot burden for baby and parents and the potential for increased compliance with the infant vaccination schedule.^{1-4,6,9}

Important Safety Information

- Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
- Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever $\geq 40.5^{\circ}\text{C}$ ($\geq 105^{\circ}\text{F}$), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥ 3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
- If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.

Important Safety Information continues on next page



Potential Impact to Your Office

With 2-3 fewer shots in the infant vaccination series compared to pentavalents (+ hepatitis B or Hib vaccine), VAXELIS may help simplify some aspects of vaccine-related tasks¹⁻⁴




Fewer Needles

Because VAXELIS requires fewer shots and does not need to be reconstituted, it can reduce the quantities of needles required.¹⁻⁴



Less Needle Waste

Incorporating VAXELIS into your practice will result in 2-3 fewer shots per patient, so for every 100 infant patients who are administered VAXELIS, there may be between 200-300 fewer needles to dispose of.¹⁻³



More Refrigerator Space

With VAXELIS, you may be able to keep fewer vaccine doses in stock. You may also be able to save room in the refrigerator due to packaging differences compared to pentavalents (+ hepatitis B or Hib vaccine).^{1-4,6,10-13}



May Reduce Administration Errors

By reducing the number of injections that must be prepped, reconstituted, and administered for each patient, there may be a reduction in errors associated with administration.^{4,6,7}

Important Safety Information

- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant's medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
- Vaccination with VAXELIS may not protect all individuals.
- The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).


Before administering VAXELIS, please read the accompanying [Prescribing Information](#). The [Patient Information](#) also is available.

Important Safety Information repeats on next page



Potential Impact on You and Your Staff

With 2-3 fewer shots in the infant vaccination series compared to pentavalents (+ hepatitis B or Hib vaccine), VAXELIS may help simplify some aspects of vaccine-related tasks¹⁻⁴



Fewer Shots Administered

The number of injections has a direct impact on the time it takes to perform vaccine-related tasks. With fewer shots across the infant vaccine series, incorporating VAXELIS into your practice may help improve efficiency and reduce administrative tasks.¹⁻⁸



Ready-to-Use Formula

VAXELIS comes in ready-to-use prefilled syringes and single dose vials—unlike *Pentacef*®, which requires reconstitution—a fully liquid vaccine formulation like VAXELIS may reduce vaccine prep time.^{1,2,5,7}



Billing and Coding

1 NDC with VAXELIS versus 2 NDCs with a pentavalent + monovalent may help reduce tasks associated with billing for vaccines.¹⁻³



Ordering and Inventory Management

Routine tasks like ordering and inventory management can be complicated. VAXELIS is a hexavalent that requires 2-3 fewer shots, so it may help reduce some of the need for additional hep B or Hib vaccines (as with pentavalents), meaning fewer vaccines to order and manage.^{1-4,6}

Important Safety Information

- Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
- Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
- Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.

Important Safety Information continues on next page



Potential Impact on Your Patients and Their Caregivers

With 2-3 fewer shots in the infant vaccination series compared to pentavalents (+ hepatitis B or Hib vaccine), VAXELIS may help simplify some aspects of vaccine-related tasks¹⁻⁴



Fewer Shots for Baby

Research has shown that the number of shots children receive in a single visit is a key parental concern. With VAXELIS, you may **reduce the shot burden** at the 2-, 4-, and 6-month visits.^{1-4,9}



May Improve Compliance

Research has shown that some parents are concerned about the number of injections their children receive during the first 2 years of life, which may lead to reduced vaccination compliance. With fewer shots needed with VAXELIS, this may **help improve vaccination compliance** in the infant series.^{1-4,6,9}

Important Safety Information

- If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
- Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever $\geq 40.5^{\circ}\text{C}$ ($\geq 105^{\circ}\text{F}$), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥ 3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.

Important Safety Information continues on next page

How Could VAXELIS Impact Your Practice Efficiency?

With 2-3 fewer shots in the infant vaccination series compared to pentavalents (+ hepatitis B or Hib vaccine), VAXELIS may help simplify some aspects of vaccine-related tasks¹⁻⁴

Office



Fewer Needles¹⁻⁴



Less Needle Waste¹⁻³



More Refrigerator Space^{1-4,6,10-13}



May Reduce Administration Errors^{4,6,7}

Staff



Fewer Shots Administered¹⁻⁸



Ready-to-Use Formula^{1,2,5,7}



Billing and Coding¹⁻³



Ordering and Inventory Management^{1-4,6}

Patients



Fewer Shots for Baby^{1-4,9}



May Improve Compliance^{1-4,6,9}

Choose the Benefits of 2-3 Fewer Shots with VAXELIS

Important Safety Information

- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant's medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
- Vaccination with VAXELIS may not protect all individuals.
- The solicited adverse reactions 0-5 days following any dose were irritability ($\geq 55\%$), crying ($\geq 45\%$), injection site pain ($\geq 44\%$), somnolence ($\geq 40\%$), injection site erythema ($\geq 25\%$), decreased appetite ($\geq 23\%$), fever $\geq 38.0^{\circ}\text{C}$ ($\geq 19\%$), injection site swelling ($\geq 18\%$), and vomiting ($\geq 9\%$).

Before administering VAXELIS, please read the accompanying [Prescribing Information](#). The [Patient Information](#) also is available.



References

1. Pentacel. Prescribing Information. Sanofi Pasteur; 2021.
2. Pentacel. Prescribing Information. Sanofi Pasteur; 2019.
3. PEDIARIX. Prescribing Information. GlaxoSmithKline; 2019.
4. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Accessed October 27, 2021. <https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf>
5. Pellissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. *Am J Manag Care*. 2000;6(9):1038-1044.
6. Centers for Disease Control and Prevention. General best practice guidelines for immunization. Accessed October 27, 2021. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html>
7. De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. *Vaccine*. 2015;33(32):3976-3982. doi:10.1016/j.vaccine.2015.06.030
8. Ciarametaro M, Bradshaw SE, Guiglotto J, Hahn B, Meier G. Hidden efficiencies: making completion of the pediatric vaccine schedule more efficient for physicians. *Medicine (Baltimore)*. 2015;94(4):e357. doi:10.1097/MD.0000000000000357
9. Kennedy A, Lavail K, Nowak G, Basket M, Landry S. Confidence about vaccines in the United States: understanding parents' perceptions. *Health Aff (Millwood)*. 2011 Jun;30(6):1151-9. doi: 10.1377/hlthaff.2011.0396
10. Sanofi Pasteur. Product Catalog, Vaccines & Biologics, VAXELIS, 1 carton of 10 prefilled syringes. VaccineShoppe.com. Accessed December 10, 2021. <https://www.vaccineshoppe.com/us/vsh/en/USD/Product-Catalog/Vaccines-%26-biologics/Vaxelis%E2%84%A2/p/243-15>
11. Sanofi Pasteur. Product Catalog, Vaccines & Biologics, VAXELIS, 1 carton 10 vials. VaccineShoppe.com. Accessed December 10, 2021. <https://www.vaccineshoppe.com/us/vsh/en/USD/Product-Catalog/Vaccines-%26-biologics/Vaxelis%E2%84%A2/p/243-10>
12. Sanofi Pasteur. Pentacel packaging update. Accessed December 10, 2021. https://www.vaccineshoppe.com/assets/pdf/SAUS.PENTC.18.09.5275_FINAL.pdf
13. GlaxoSmithKline. PEDIARIX pre-filled syringe ordering information. Accessed December 10, 2021. <https://www.gskdirect.com/gsk/en/USD/RootCategory/Vaccines%28non-flu%29/PEDIARIX-PFS1DOSE-0-5ML-NO-NDL-10S-LM/p/58160081152?pro-from=product-list>